miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras
► MicroRNA-181a (miR-181a) was frequently downregulated in oral squamous cell carcinoma (OSCC). ► Overexpression of miR-181a suppressed OSCC growth. ► K-ras is a novel target of miR-181a. ► Decreased miR-181a expression is attributed to its lower promoter activity in OSCC. MicroRNAs (miRNAs) are epi...
Gespeichert in:
Veröffentlicht in: | Biochemical and biophysical research communications 2011-01, Vol.404 (4), p.896-902 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | ► MicroRNA-181a (miR-181a) was frequently downregulated in oral squamous cell carcinoma (OSCC). ► Overexpression of miR-181a suppressed OSCC growth. ► K-ras is a novel target of miR-181a. ► Decreased miR-181a expression is attributed to its lower promoter activity in OSCC.
MicroRNAs (miRNAs) are epigenetic regulators of gene expression, and their deregulation plays an important role in human cancer, including oral squamous cell carcinoma (OSCC). Recently, we found that miRNA-181a (miR-181a) was upregulated during replicative senescence of normal human oral keratinocytes. Since senescence is considered as a tumor suppressive mechanism, we thus investigated the expression and biological role of miR-181a in OSCC. We found that miR-181a was frequently downregulated in OSCC. Ectopic expression of miR-181a suppressed proliferation and anchorage independent growth ability of OSCC. Moreover, miR-181a dramatically reduces the growth of OSCC on three dimensional organotypic raft culture. We also identified K-ras as a novel target of miR-181a. miR-181a decreased K-ras protein level as well as the luciferase activity of reporter vectors containing the 3′-untranslated region of K-ras gene. Finally, we defined a minimal regulatory region of miR-181a and found a positive correlation between its promoter activity and the level of miR-181a expression. In conclusion, miR-181a may function as an OSCC suppressor by targeting on K-ras oncogene. Thus, miR-181a should be considered for therapeutic application for OSCC. |
---|---|
ISSN: | 0006-291X 1090-2104 |
DOI: | 10.1016/j.bbrc.2010.12.055 |